Trial · NCT00762645
Travoprost 0.004% Versus Pilocarpine 1% in Patients With Chronic Angle Closure Glaucoma (CACG)
NCT00762645, Phase 4, Completed, Alcon Research; results first posted 2010-03-15
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Travoprost 0.004% Versus Pilocarpine 1% in Patients With Chronic Angle Closure Glaucoma (CACG). Trials, record NCT00762645. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00762645
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Travoprost 0.004% Versus Pilocarpine 1% in Patients With Chronic Angle Closure Glaucoma (CACG)
- NCT number
- NCT00762645
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 30 participants, actual
- Lead sponsor
- Alcon Research
- Conditions
- Angle-closure Glaucoma
- Interventions
- Travoprost 0.004% (Travatan), Pilocarpine 1%
- First posted
- 2008-09-30
- Last updated
- 2023-12-06
- Results first posted
- 2010-03-15
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mean Intraocular Pressure (IOP) | 4PM at Week 12 Visit | |
| Secondary | Number of Patients With Peripheral Anterior Synechiae (PAS) | Week 12 Visit |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Mean Intraocular Pressure (IOP) | 4PM at Week 12 Visit | millimeters mercury (mm Hg) | MEAN | |
| SECONDARY | Number of Patients With Peripheral Anterior Synechiae (PAS) | Week 12 Visit | Participants | NUMBER |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Mean Intraocular Pressure (IOP) | Travoprost 0.004% (Travatan) | 15.77 | Standard Deviation 2.32 | millimeters mercury (mm Hg) | |
| Mean Intraocular Pressure (IOP) | Pilocarpine 1% | 18.35 | Standard Deviation 3.72 | millimeters mercury (mm Hg) | |
| Number of Patients With Peripheral Anterior Synechiae (PAS) | Travoprost 0.004% (Travatan) | 0 | Participants | ||
| Number of Patients With Peripheral Anterior Synechiae (PAS) | Pilocarpine 1% | 0 | Participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Travoprost 0.004% (Travatan) | 16 | |
| Overall Study | STARTED | Pilocarpine 1% | 14 | |
| Overall Study | COMPLETED | Travoprost 0.004% (Travatan) | 12 | |
| Overall Study | COMPLETED | Pilocarpine 1% | 12 | |
| Overall Study | NOT COMPLETED | Travoprost 0.004% (Travatan) | 4 | |
| Overall Study | NOT COMPLETED | Pilocarpine 1% | 2 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Travoprost 0.004% (Travatan) | ||
| Total, all-cause mortality | Pilocarpine 1% | ||
| Total, other adverse events | Travoprost 0.004% (Travatan) | 0 | 16 |
| Total, other adverse events | Pilocarpine 1% | 0 | 14 |
| Total, serious adverse events | Travoprost 0.004% (Travatan) | 0 | 16 |
| Total, serious adverse events | Pilocarpine 1% | 0 | 14 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Travoprost 0.004% (Travatan) vs Pilocarpine 1%: Number of Patients With Peripheral Anterior Synechiae (PAS) | Trial comparisons |
| Travoprost 0.004% (Travatan) vs Pilocarpine 1%: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00762645
GET https://conductscience.org/api/trials/v1/NCT00762645/registered